Suppr超能文献

R.E.N.A.L. 肾脏肿瘤解剖评分系统对 751 例经皮消融肾脏肿瘤的疗效及并发症预测价值。

Usefulness of R.E.N.A.L. nephrometry scoring system for predicting outcomes and complications of percutaneous ablation of 751 renal tumors.

机构信息

Department of Radiology, Mayo Clinic School of Medicine, Rochester, Minnesota 55905, USA.

出版信息

J Urol. 2013 Jan;189(1):30-5. doi: 10.1016/j.juro.2012.08.180. Epub 2012 Nov 16.

Abstract

PURPOSE

We applied the R.E.N.A.L. (radius, exophytic/endophytic, nearness to collecting system or sinus, anterior/posterior and location relative to polar lines) nephrometry scoring system to renal tumors treated with percutaneous ablation to determine whether this score is associated with oncological outcomes and complications.

MATERIALS AND METHODS

A total of 751 renal tumors were treated at 679 percutaneous ablation sessions in 627 patients at our institution between 2000 and 2012. Of these renal masses 430 (57%) were treated with cryoablation and the remaining 321 were treated with radio frequency ablation. R.E.N.A.L. tumor scores were analyzed to determine the association of the score with ablation treatment outcomes and complications according to Clavien criteria.

RESULTS

The mean ± SD R.E.N.A.L. nephrometry score of all ablated tumors was 6.7 ± 1.9. Those treated with cryoablation had higher scores than those treated with radio frequency ablation (mean 7.2 ± 1.9 vs 6.1 ± 1.8, p <0.001). We identified a total of 28 local treatment failures (3.7%) in the 751 tumors during a mean computerized tomography/magnetic resonance imaging followup of 27.9 ± 27.8 months. There was a significant association between R.E.N.A.L. nephrometry score and local treatment failure. Mean nephrometry score was 7.6 ± 2.2 vs 6.7 ± 1.9 for tumors with vs without local treatment failure (p <0.001). Of the 679 ablation treatments 38 (5.6%) major (grade 3 or greater) patient complications occurred. There was a significant association between R.E.N.A.L. nephrometry score and major complications. Patients with vs without a major complication had a mean nephrometry score of 8.1 ± 2.0 vs 6.8 ± 1.9 (p <0.001).

CONCLUSIONS

The R.E.N.A.L. nephrometry scoring system predicts treatment efficacy and complications following percutaneous renal ablation.

摘要

目的

我们将 R.E.N.A.L.(半径、外生/内生、靠近集合系统或窦、前后和相对于极线的位置)肾肿瘤评分系统应用于经皮消融治疗的肾肿瘤,以确定该评分是否与肿瘤学结果和并发症相关。

材料与方法

在 2000 年至 2012 年期间,我们在 679 次经皮消融治疗中对 627 名患者的 751 个肾肿瘤进行了治疗。这些肾肿瘤中,430 个(57%)采用冷冻消融治疗,其余 321 个采用射频消融治疗。分析 R.E.N.A.L.肿瘤评分,以根据 Clavien 标准确定评分与消融治疗结果和并发症的相关性。

结果

所有消融肿瘤的平均±SD R.E.N.A.L.肾肿瘤评分(nephrometry score)为 6.7±1.9。接受冷冻消融治疗的肿瘤评分高于接受射频消融治疗的肿瘤(平均 7.2±1.9 与 6.1±1.8,p<0.001)。在 751 个肿瘤的平均计算机断层扫描/磁共振成像随访 27.9±27.8 个月期间,共发现 28 个局部治疗失败(3.7%)。R.E.N.A.L.肾肿瘤评分与局部治疗失败显著相关。局部治疗失败的肿瘤评分(mean nephrometry score)为 7.6±2.2,无局部治疗失败的肿瘤评分(mean nephrometry score)为 6.7±1.9(p<0.001)。在 679 次消融治疗中,38 次(5.6%)出现 3 级或更高级别的主要(grade 3 or greater)患者并发症。R.E.N.A.L.肾肿瘤评分与主要并发症显著相关。有或无主要并发症的患者的平均肾肿瘤评分分别为 8.1±2.0 和 6.8±1.9(p<0.001)。

结论

R.E.N.A.L.肾肿瘤评分系统预测经皮肾消融治疗的疗效和并发症。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验